Paul Badawi, the President and CEO of Sight Sciences , Inc. (NASDAQ:), reported a sale of 24,819 shares of the company’s common stock. The transaction, which took place on January 16, 2025, was executed at a weighted average price of $2.924 per share, resulting in a total value of approximately $72,570. The sale comes amid challenging market conditions for SGHT, with the stock down over 63% in the past six months and currently trading near its 52-week low of $2.67. Following this sale, Badawi retains ownership of 5,676,331 shares directly. The shares were sold to cover tax liabilities associated with the vesting of restricted stock units. While InvestingPro analysis indicates the company maintains strong liquidity with a current ratio of 10.18 and holds more cash than debt, the stock appears undervalued according to InvestingPro’s Fair Value model. Investors can access detailed analysis and 10 additional key insights about SGHT through InvestingPro’s comprehensive research report.
In other recent news, Sight Sciences Inc. has been facing adjustments and predictions from various financial firms. Lake Street Capital Markets has revised Sight Sciences’ price target from $5.00 to $3.00, maintaining a Hold rating on the company’s shares. This adjustment follows recent changes in Medicare coverage, affecting the industry and Sight Sciences’ market share. Despite these challenges, the company is actively managing its finances to maintain liquidity.
Sight Sciences has also projected modest revenue growth in Q4 2024, driven by surgical glaucoma product sales. The company’s preliminary financial results for the fourth quarter and full year of 2024 indicate a slight increase in total revenue for the quarter, while annual revenue is expected to decline by 2% compared to 2023. However, surgical glaucoma revenues are expected to grow by 2%.
A recent study showed the effectiveness of Sight Sciences’ OMNI Surgical System in reducing intraocular pressure in patients with primary open-angle glaucoma. Furthermore, the company has secured an additional $5 million in loan funding from its existing credit facility with Hercules Capital (NYSE:), Inc. and affiliates, raising the total borrowed amount to $40 million.
UBS has initiated coverage of Sight Sciences with a Buy rating, forecasting strong sales growth by 2026. The UBS analyst expects the company’s TearCare Dry Eye solution to drive double-digit sales growth and gross margin expansion that exceeds consensus estimates…
Click Here to Read the Full Original Article at All News…
